PT Pyridam Farma Tbk

As of June 30, 2026, PT Pyridam Farma Tbk carries a market capitalization of 1.96T, placing it among publicly traded companies globally. Its enterprise value stands at 7.43T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, PT Pyridam Farma Tbk has 11.24B shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.65, and the price-to-book ratio stands at 2.86.

These figures are as of June 30, 2026. The EV/Sales ratio of 2.48 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 7.43T versus a market cap of 1.96T, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, PT Pyridam Farma Tbk maintains a current ratio of 0.85, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 598.94, indicating elevated leverage, while an interest coverage ratio of -0.14 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, PT Pyridam Farma Tbk posted a negative return on equity (ROE) of -44.76, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -4.84, reflecting losses generated across the asset base. The company generates approximately 1.34B in revenue per employee across its workforce of 2,241.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.68 indicates how many times PT Pyridam Farma Tbk sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, PT Pyridam Farma Tbk recorded an income tax benefit of -142.66B rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -487.40B and -344.75B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, PT Pyridam Farma Tbk's stock has declined approximately 67.82% over the past 52 weeks. The 50-day moving average sits at 228.52, while the 200-day moving average is 298.79.

Over the twelve months ended June 30, 2026, PT Pyridam Farma Tbk generated 2.99T in revenue and converted that into -344.75B in net income, yielding earnings per share of -30.68. EBITDA reached -47.24B, while operating income came in at -121.84B.

As of June 30, 2026, PT Pyridam Farma Tbk holds 130.31B in cash and equivalents against 5.39T in total debt, resulting in a net debt position of 3.96T. Total book value stands at 684.19B, with working capital of -278.88B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, PT Pyridam Farma Tbk posted a gross margin of 21.99, reflecting its pricing power and cost economics. The operating margin of -4.07 and net profit margin of -11.52 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Total shareholder yield is negative at -22.11, meaning PT Pyridam Farma Tbk raised more capital through share issuance and new debt than it returned via dividends and buybacks.

PT Pyridam Farma Tbk's most recent stock split took place on April 22, 2024 with a 441:2054 split ratio.

As of June 30, 2026, PT Pyridam Farma Tbk has an Altman Z-Score of 0.50, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.